Tim Dudderidge

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10511883/publications.pdf

Version: 2024-02-01

23 papers	2,000 citations	516710 16 h-index	610901 24 g-index
24 all docs	24 docs citations	24 times ranked	4743 citing authors

#	Article	IF	Citations
1	Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience. European Urology, 2022, 81, 407-413.	1.9	41
2	Focal HIFU therapy for anterior compared to posterior prostate cancer lesions. World Journal of Urology, 2021, 39, 1115-1119.	2.2	23
3	Assessment of Return to Baseline Urinary and Sexual Function Following Primary Focal Cryotherapy for Nonmetastatic Prostate Cancer. European Urology Focus, 2021, 7, 301-308.	3.1	11
4	Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study. Prostate Cancer and Prostatic Diseases, 2021, 24, 567-574.	3.9	28
5	Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial. BMJ Open, 2021, 11, e042953.	1.9	15
6	Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour control. Prostate Cancer and Prostatic Diseases, 2021, 24, 1120-1128.	3.9	10
7	A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. Lancet Oncology, The, 2021, 22, 1618-1631.	10.7	48
8	Focal therapy, time to join the multi-disciplinary team discussion?. Translational Andrology and Urology, 2020, 9, 1526-1534.	1.4	4
9	Highâ€intensity focused ultrasound focal therapy for prostate cancer. Trends in Urology & Men's Health, 2020, 11, 15-18.	0.4	1
10	Evaluation of functional outcomes after a second focal highâ€intensity focused ultrasonography (HIFU) procedure in men with primary localized, nonâ€metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry. BJU International, 2020, 125, 853-860.	2.5	23
11	Comparative Healthcare Research Outcomes of Novel Surgery in prostate cancer (IP4-CHRONOS): A prospective, multi-centre therapeutic phase II parallel Randomised Control Trial. Contemporary Clinical Trials, 2020, 93, 105999.	1.8	20
12	An Exploratory Study of Dose Escalation vs Standard Focal High-Intensity Focused Ultrasound for Treating Nonmetastatic Prostate Cancer. Journal of Endourology, 2020, 34, 641-646.	2.1	7
13	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. European Urology, 2019, 76, 831-842.	1.9	148
14	Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. European Urology, 2019, 76, 98-105.	1.9	96
15	Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nature Genetics, 2018, 50, 682-692.	21.4	182
16	A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. European Urology, 2018, 74, 422-429.	1.9	220
17	Overcoming difficulties with equipoise to enable recruitment to a randomised controlled trial of partial ablation vs radical prostatectomy for unilateral localised prostate cancer. BJU International, 2018, 122, 970-977.	2.5	17
18	Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study. Health Technology Assessment, 2018, 22, 1-176.	2.8	70

#	Article	IF	Citations
19	PD56-08 THE PART TRIAL - A PHASE III STUDY COMPARING PARTIAL PROSTATE ABLATION VERSUS RADICAL PROSTATECTOMY (PART) IN INTERMEDIATE RISK PROSTATE CANCER â€“ EARLY DATA FROM THE FEASIBILITY STUDY. Journal of Urology, 2017, 197, .	0.4	3
20	Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data. PLoS Genetics, 2017, 13, e1007001.	3.5	34
21	Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nature Genetics, 2015, 47, 367-372.	21.4	380
22	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nature Genetics, 2013, 45, 385-391.	21.4	492
23	A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Human Molecular Genetics, 2013, 22, 408-415.	2.9	118